Search Browse Earnings

VOLITIONRX LTD

NYSE:VNRX

In Vitro & In Vivo Diagnostic Substances·HENDERSON, NV

Overview All Filings Sum Fin Credit Insiders Governance

Overview All Filings Sum Fin Credit Insiders Governance

Summary Financials

VOLITIONRX LTD — SlamSEC

Revenue

$775,302

+153.0% YoY

FY 2024

Adj. EBITDA

-$34.8M

-4493.1% margin

FY 2024

Net Income

-$35.7M

-4601.7% margin

FY 2024

EPS (Diluted)

-$0.50

FY 2024

Stock Price

$0.20

+0.1%

2026-03-10

52W Range

$0.17 – $0.94

P/E Ratio

-0.4x

Market Cap

$24.6M

Cash

$20.7M

FY 2024

Total Debt

$4.1M

FY 2024

Net Cash

$16.7M

FY 2024

Enterprise Value

$7.9M

Debt / EBITDA

0.5x

FY 2024

EV / EBITDA

-0.2x

Employees

—